retatrutide nonalcoholic steatohepatitis trial Liraglutide safety and efficacy in patients with non-alcoholic (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study NASH Study | Fatty Liver

Taking an unregulated version means you bypass the safety monitoring built into clinical programmes

In the United States alone, the number of patients starting GLP-1 treatments for non-diabetic purposes has increased by 700% since 2019, with estimates suggesting that over 220,000 patients started treatment each month in 2024

Knop et al., 2023

These experts typically have specialized knowledge in areas such as pharmacology, toxicology, or medicine, allowing them to analyze complex issues related to defective drugs

doi:10.1016/j.fertnstert.2023.10.017 Andersen, J

Gastric bypass prevents diabetes in genetically modified mice and chemically induced diabetic mice